C. Zagoya

发表

Had it happened without Christmas? Thoracic emphysema and Allergic Bronchopulmonary Aspergillosis in a juvenile CF-patient with G551D receiving ivacaftor

J. Mainz, N. Erdmann, F. Duckstein, 2021 .

The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis

J. Mainz, R. Mauch, F. Duckstein, 2022, Expert review of respiratory medicine.

Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with CFTR Mutations Causing Pancreatic Insufficiency

J. Mainz, T. Lehmann, S. Lüth, 2022, International journal of molecular sciences.

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid

J. Mainz, J. Hentschel, U. Hipler, 2021, Frontiers in Immunology.

Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage

J. Mainz, J. Hentschel, T. Lehmann, 2022, Frontiers in Immunology.

How to obtain the Lorentz space contraction formula for a moving rod from knowledge of the positions of its ends at different times

M. F. Guasti, C. Zagoya, 2009 .

Interference nature of quantum breather oscillation

L. Schulman, F. Grossmann, C. Zagoya, 2014 .

Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis

J. Mainz, M. Lorenz, U. Hipler, 2021, Journal of pediatric gastroenterology and nutrition.

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

J. Mainz, D. Peckham, O. Eickmeier, 2022, Frontiers in Pharmacology.

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.

J. Mainz, A. Jones, R. Floto, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

565: Significant reduction in abdominal symptoms assessed with CFAbd score over 4 weeks of treatment with elexacaftor/tezacaftor/ivacaftor—First results from the RECOVER study

J. Mainz, J. Davies, B. Linnane, 2021, Journal of Cystic Fibrosis.

Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor

J. Mainz, N. Erdmann, F. Duckstein, 2021, ERJ Open Research.

Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria.

J. Mainz, A. Ribeiro, E. Lomazi, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

An analytical approach to high harmonic generation

F. Grossmann, J. Rost, C. Zagoya, 2012 .

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged >=12 years - The RECOVER study

J. Mainz, D. Cox, J. Davis, 2023, medRxiv.

Quantum and semiclassical phase-space dynamics of a wave packet in strong fields using initial-value representations

D. Shalashilin, M. Rontó, C. F. D. M. Faria, 2014, 1405.2873.

Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire

J. Mainz, O. Eickmeier, C. Schwarz, 2023, medRxiv.

Dominant-interaction Hamiltonians for high-order-harmonic generation in laser-assisted collisions

F. Grossmann, J. Rost, C. Zagoya, 2012 .

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.

J. Mainz, D. Cox, B. Linnane, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.